The Filings Report

ImmunityBio, Inc. Common Stock

IBRXNasdaqCIK 1326110Healthcare / Biotechnologyfiscal year ends December50 quarters since 2014

Revenue, Q2 FY2026
$51M
+93.9% on Q2 FY2025
Net income
−$230M
−148.9% on Q2 FY2025
Free cash flow
−$70M
+13.4% on Q2 FY2025
Diluted EPS
$-0.22
−120.0% on Q2 FY2025
Revenue, TTM
$166M
trailing four quarters
Net margin, TTM
-598.6%
net income −$992M
Free cash flow, TTM
−$288M
−$281M less $7M capex
Cash and equivalents
$76M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+12.1%
1.06B shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$8.4B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, ImmunityBio, Inc. Common Stock reported revenue of $51M, +93.9% on Q2 FY2025, and net loss of $230M (−148.9%). Net income this quarter is driven by non-operating items: −$169M of other income against −$62M of operating income, so it reflects gains or losses outside the operations. Operating margin was −120.4%. Free cash flow, operating cash flow less capital expenditures, was −$70M (−$66M less $4M). Diluted earnings per share were $-0.22.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 4, 2026.

Revenue and net incomeRevenueNet income
−$800M−$600M−$400M−$200M$0$200MQ3'22, Revenue: $118KQ3'22, Net income: −$111MQ3'22Q4'22, Revenue: $73KQ4'22, Net income: −$108MQ4'22Q1'23, Revenue: $360KQ1'23, Net income: −$116MQ1'23Q2'23, Revenue: $41KQ2'23, Net income: −$138MQ2'23Q3'23, Revenue: $82KQ3'23, Net income: −$96MQ3'23Q4'23, Revenue: $139KQ4'23, Net income: −$233MQ4'23Q1'24, Revenue: $40KQ1'24, Net income: −$134MQ1'24Q2'24, Revenue: $1MQ2'24, Net income: −$135MQ2'24Q3'24, Revenue: $6MQ3'24, Net income: −$86MQ3'24Q4'24, Revenue: $8MQ4'24, Net income: −$59MQ4'24Q1'25, Revenue: $17MQ1'25, Net income: −$130MQ1'25Q2'25, Revenue: $26MQ2'25, Net income: −$93MQ2'25Q3'25, Revenue: $32MQ3'25, Net income: −$67MQ3'25Q4'25, Revenue: $38MQ4'25, Net income: −$62MQ4'25Q1'26, Revenue: $44MQ1'26, Net income: −$633MQ1'26Q2'26, Revenue: $51MQ2'26, Net income: −$230MQ2'26−$800M−$600M−$400M−$200M$0$200MQ3'22, Revenue: $118KQ3'22, Net income: −$111MQ4'22, Revenue: $73KQ4'22, Net income: −$108MQ4'22Q1'23, Revenue: $360KQ1'23, Net income: −$116MQ2'23, Revenue: $41KQ2'23, Net income: −$138MQ2'23Q3'23, Revenue: $82KQ3'23, Net income: −$96MQ4'23, Revenue: $139KQ4'23, Net income: −$233MQ4'23Q1'24, Revenue: $40KQ1'24, Net income: −$134MQ2'24, Revenue: $1MQ2'24, Net income: −$135MQ2'24Q3'24, Revenue: $6MQ3'24, Net income: −$86MQ4'24, Revenue: $8MQ4'24, Net income: −$59MQ4'24Q1'25, Revenue: $17MQ1'25, Net income: −$130MQ2'25, Revenue: $26MQ2'25, Net income: −$93MQ2'25Q3'25, Revenue: $32MQ3'25, Net income: −$67MQ4'25, Revenue: $38MQ4'25, Net income: −$62MQ4'25Q1'26, Revenue: $44MQ1'26, Net income: −$633MQ2'26, Revenue: $51MQ2'26, Net income: −$230MQ2'26

Net income losses drawn in red.

Free cash flow
−$150M−$100M−$50M$0$50MQ3'22, Free cash flow: −$97MQ3'22Q4'22, Free cash flow: −$110MQ4'22Q1'23, Free cash flow: −$93MQ1'23Q2'23, Free cash flow: −$88MQ2'23Q3'23, Free cash flow: −$93MQ3'23Q4'23, Free cash flow: −$123MQ4'23Q1'24, Free cash flow: −$108MQ1'24Q2'24, Free cash flow: −$101MQ2'24Q3'24, Free cash flow: −$102MQ3'24Q4'24, Free cash flow: −$87MQ4'24Q1'25, Free cash flow: −$87MQ1'25Q2'25, Free cash flow: −$81MQ2'25Q3'25, Free cash flow: −$70MQ3'25Q4'25, Free cash flow: −$71MQ4'25Q1'26, Free cash flow: −$77MQ1'26Q2'26, Free cash flow: −$70MQ2'26−$150M−$100M−$50M$0$50MQ3'22, Free cash flow: −$97MQ4'22, Free cash flow: −$110MQ4'22Q1'23, Free cash flow: −$93MQ2'23, Free cash flow: −$88MQ2'23Q3'23, Free cash flow: −$93MQ4'23, Free cash flow: −$123MQ4'23Q1'24, Free cash flow: −$108MQ2'24, Free cash flow: −$101MQ2'24Q3'24, Free cash flow: −$102MQ4'24, Free cash flow: −$87MQ4'24Q1'25, Free cash flow: −$87MQ2'25, Free cash flow: −$81MQ2'25Q3'25, Free cash flow: −$70MQ4'25, Free cash flow: −$71MQ4'25Q1'26, Free cash flow: −$77MQ2'26, Free cash flow: −$70MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300MQ3'22, Cash and equivalents: $104MQ3'22Q4'22, Cash and equivalents: $105MQ4'22Q1'23, Cash and equivalents: $88MQ1'23Q2'23, Cash and equivalents: $44MQ2'23Q3'23, Cash and equivalents: $178MQ3'23Q4'23, Cash and equivalents: $265MQ4'23Q1'24, Cash and equivalents: $133MQ1'24Q2'24, Cash and equivalents: $130MQ2'24Q3'24, Cash and equivalents: $112MQ3'24Q4'24, Cash and equivalents: $143MQ4'24Q1'25, Cash and equivalents: $61MQ1'25Q2'25, Cash and equivalents: $138MQ2'25Q3'25, Cash and equivalents: $60MQ3'25Q4'25, Cash and equivalents: $88MQ4'25Q1'26, Cash and equivalents: $205MQ1'26Q2'26, Cash and equivalents: $76MQ2'26$0$100M$200M$300MQ3'22, Cash and equivalents: $104MQ4'22, Cash and equivalents: $105MQ4'22Q1'23, Cash and equivalents: $88MQ2'23, Cash and equivalents: $44MQ2'23Q3'23, Cash and equivalents: $178MQ4'23, Cash and equivalents: $265MQ4'23Q1'24, Cash and equivalents: $133MQ2'24, Cash and equivalents: $130MQ2'24Q3'24, Cash and equivalents: $112MQ4'24, Cash and equivalents: $143MQ4'24Q1'25, Cash and equivalents: $61MQ2'25, Cash and equivalents: $138MQ2'25Q3'25, Cash and equivalents: $60MQ4'25, Cash and equivalents: $88MQ4'25Q1'26, Cash and equivalents: $205MQ2'26, Cash and equivalents: $76MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

ImmunityBio, Inc. Common Stock income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 12, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue51443832261786+93.9%
Cost of revenue00000000+119.1%
Gross profit—————————
Research and development——————3550—
Selling, general and administrative——————4236—
Operating income(62)(70)(65)(56)(71)(64)(69)(80)+13.5%
Other income (expense)(169)(563)3(12)(21)(65)10(5)−702.5%
Pretax income(230)(633)(62)(67)(92)(130)(59)(86)−149.6%
Income tax00000000−100.0%
Net income(230)(633)(62)(67)(93)(130)(59)(86)−148.9%
Diluted EPS ($)(0.22)(0.62)—(0.07)(0.10)(0.15)—(0.14)−120.0%
Diluted shares (millions)1,0501,027—947888853—698—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

ImmunityBio, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 12, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents76205886013861143112−45.0%
Short-term investments282176154198161618+1660.6%
Total current assets439453315329208109185163+110.9%
Total assets629647502519402304383365+56.3%
Total current liabilities7768625751495561+51.5%
Long-term debt—————————
Total liabilities1,6741,5161,0011,0429728948711,109+72.3%
Stockholders’ equity(1,047)(870)(500)(524)(571)(591)(489)(745)−83.4%
Shares outstanding (millions)1,0601,0471,028985945883853697—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

ImmunityBio, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 12, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow(66)(75)(70)(69)(80)(86)(85)(99)+16.6%
Capital expenditures42111123+225.3%
Free cash flow (CFO − capex)(70)(77)(71)(70)(81)(87)(87)(102)+13.4%
Depreciation and amortization44444444+13.6%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 23, 2026.

Income statement

ImmunityBio, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Mar 19, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 4, 2021FY2019ended Dec 31, 2019filed Mar 25, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 30, 2016FY2014ended Dec 31, 2014filed Sep 10, 2015FY2013ended Dec 31, 2013filed Sep 10, 2015
Revenue1131510112000011
Cost of revenue1000—————————
Gross profit—————————————
Research and development—1902322481961401125642291120
Selling, general and administrative—169130103135714643579522852
Operating income(256)(344)(362)(351)(330)(221)(156)(98)(99)(124)(239)(6)—
Other income (expense)(96)(69)(222)(66)(20)(5)(4)2232(1)—
Pretax income(352)(414)(584)(417)(350)(226)(160)(97)(97)(121)(237)(6)—
Income tax00000(2)0(1)0(1)000
Net income(351)(414)(583)(417)(347)(222)(158)(96)(96)(121)(237)(6)(2)
Diluted EPS ($)(0.38)(0.62)(1.15)(1.04)(0.89)(0.59)(0.43)——————
Diluted shares (millions)920700509400389377366——————

Balance sheet

ImmunityBio, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Mar 19, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 4, 2021FY2019ended Dec 31, 2019filed Mar 25, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 30, 2016FY2014ended Dec 31, 2014filed Sep 10, 2015FY2013ended Dec 31, 2013filed Sep 10, 2015
Cash and equivalents88143265105181357617248176590
Short-term investments154613136613657104191118——
Total current assets315185294141334112568913220529859—
Total assets50238350436246922114318225031736761—
Total current liabilities625558501369681227211362—
Long-term debt—————————————
Total liabilities1,0018711,09081271334022363224112—
Stockholders’ equity(500)(489)(587)(447)(242)(120)12114621929335658(4)
Shares outstanding (millions)1,0288536744363981099879798282——

Cash flow statement

ImmunityBio, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Mar 19, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed Mar 4, 2021FY2019ended Dec 31, 2019filed Mar 25, 2020FY2018ended Dec 31, 2018filed Mar 13, 2019FY2017ended Dec 31, 2017filed Mar 12, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 30, 2016FY2014ended Dec 31, 2014filed Sep 10, 2015FY2013ended Dec 31, 2013filed Sep 10, 2015
Operating cash flow(305)(391)(367)(338)(274)(172)(152)(63)(49)(39)———
Capital expenditures473178342413357200
Free cash flow (CFO − capex)(309)(398)(397)(416)(308)(173)(156)(76)(84)(45)———
Depreciation and amortization161819181413141064100
Share repurchases————0030151650—
Dividends paid—————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$1M
2 sales by 2 insiders; officers and directors $1M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$10M
16 sales by 3 insiders; officers and directors $10M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 5, 2026Simon Barry J.Directoropen-market sale10b5-125,000$10.75$269K3MOct 6, 2026
Oct 2, 2026Cohen CherylDirectoroption exercise55,979$2.98$167K181,365Oct 6, 2026
Oct 2, 2026Cohen CherylDirectoropen-market sale10b5-181,056$10.50$851K100,309Oct 6, 2026
Jul 2, 2026Cohen CherylDirectoroption exercise55,979$2.98$167K256,596Jul 6, 2026
Jul 2, 2026Cohen CherylDirectoropen-market sale10b5-1131,210$9.50$1M125,386Jul 6, 2026
Jul 1, 2026Selecky ChristobelDirectoroption exercise35,064$2.98$104K35,064Jul 6, 2026
Jul 1, 2026Selecky ChristobelDirectoroption exercise124,414$2.99$372K159,478Jul 6, 2026
Jul 1, 2026Selecky ChristobelDirectoropen-market sale10b5-1159,478$9.02$1M0Jul 6, 2026
Jun 30, 2026Selecky ChristobelDirectoroption exercise700$2.98$2K700Jul 1, 2026
Jun 30, 2026Selecky ChristobelDirectoroption exercise300$2.99$8971,000Jul 1, 2026
Jun 30, 2026Selecky ChristobelDirectoropen-market sale10b5-11,000$9.00$9K0Jul 1, 2026
Jun 29, 2026Selecky ChristobelDirectoroption exercise32,173$2.98$96K32,173Jul 1, 2026
Jun 29, 2026Selecky ChristobelDirectoroption exercise33,549$2.99$100K65,722Jul 1, 2026
Jun 29, 2026Selecky ChristobelDirectoroption exercise30,000$2.84$85K95,722Jul 1, 2026
Jun 29, 2026Selecky ChristobelDirectoropen-market sale10b5-195,722$9.01$862K0Jul 1, 2026
Jun 24, 2026Simon Barry J.Directoropen-market sale10b5-125,000$7.88$197K3MJun 26, 2026
Jun 4, 2026Simon Barry J.Directoropen-market sale10b5-123,033$7.18$165K3MJun 5, 2026
Mar 31, 2026Soon-Shiong Patrick+4 moreSee remarks, Director, 10% ownerconversionindirect5M$5.43$25M251MApr 2, 2026
Feb 24, 2026Simon Barry J.Directoropen-market sale10b5-175,000$12.01$901K3MFeb 26, 2026
Feb 23, 2026Selecky ChristobelDirectoroption exercise25,000$2.98$75K25,000Feb 24, 2026
Feb 23, 2026Selecky ChristobelDirectoropen-market sale10b5-125,000$10.00$250K0Feb 24, 2026
Feb 23, 2026Simon Barry J.Directoropen-market sale10b5-1165,000$10.25$2M3MFeb 24, 2026
Feb 22, 2026Sachs David C.Chief Financial Officertax withholding20,682$8.70$180K300,143Feb 24, 2026
Feb 22, 2026Sachs David C.Chief Financial Officeroption exercise40,650$0.00—320,825Feb 24, 2026
Feb 22, 2026California Capital Equity, LLC+4 more10% ownertax withholding58,170$8.70$506K30MFeb 24, 2026

Full insider history for ImmunityBio, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
IMMUNITYBIO, INC., CIK 1326110 on EDGAR
Extract generated
November 4, 2026
Withheld
6 line-years whose four quarters do not sum to the filed year: net income FY2019, operating income FY2019, revenue FY2019, net income FY2020, operating income FY2020, revenue FY2020
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/IBRX.json